1.
Mato AR, Sharman JP, Biondo JM, Wu M, Mun Y, Kim SY, Humphrey K, Boyer M, Zhu Q, Seymour JF. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i&gt; analyses from the phase III MURANO study. haematol [Internet]. 2022Jan.1 [cited 2024May25];107(1):134-42. Available from: https://haematologica.org/article/view/haematol.2020.266486